it's breast cancer, but we love the news anyway!
"...is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere."
biospace.com/press-releases...
we must resist!!
great news… and Bria-PROS+ - their immunotherapy drug for PCa is going into trials this year.
This calls for an article!!
This calls for an article!!
MOA of Bria-PROS+
These are both what we have been pushing for. More personalized treatment.
The skeptic in me says they will get bought out and squashed, but my optimistic side says they will get bought out and funded for phase3 and fast tracked and we will see a leap forward in this approach to curing cancer.
ChatGPT
Bria-PROS+™ is a personalized off-the-shelf immunotherapy developed by BriaCell Therapeutics, specifically targeting prostate cancer. Its mechanism of action involves the activation of both the innate and adaptive immune systems to elicit a robust anti-cancer response.
Key Mechanisms:
1. Activation of the Innate Immune System:
• Natural Killer (NK) and NKT Cell Activation: Bria-PROS+™ stimulates NK and NKT cells, which are crucial components of the body’s first line of defense against cancer. This activation is mediated by molecules such as CD86, IL-12, and NKG2D, and is inhibited by HLA class I molecules. 
2. Stimulation of the Adaptive Immune System:
• Helper (CD4+) and Cytotoxic (CD8+) T Cell Activation: The therapy enhances the activation of both helper and cytotoxic T cells, leading to a targeted immune response against prostate cancer cells. 
3. Expression of Immune-Activating Factors:
• Cytokines and Co-Stimulatory Molecules: Bria-PROS+™ is engineered to express multiple immune-activating cytokines (e.g., IL-12, IL-7, GM-CSF, IFN-α) and co-stimulatory molecules (e.g., CD86, CD80, 4-1BBL), enhancing its ability to stimulate the immune system. 
4. Antigen Presentation:
• Tumor-Associated Antigens (TAAs) and Post-Translational Modifications (PTMs): The therapy presents a variety of TAAs and PTMs to the immune system, promoting the recognition and targeting of prostate cancer cells. 
By engaging these mechanisms, Bria-PROS+™ aims to provide a potent and durable anti-cancer effect, offering a promising therapeutic option for patients with prostate cancer.
Ready to crowdfund them!
Wow thats an idea! Do you think enough money could be raised to out bid pharma?
Not sure, not sure also about where big pharma starts...these guys are already running a phase 3 trial and are listed on nasdaq...I see many small pharma companies reaching partnership and commercialization stage, look at Vertex and Crispr Therapeutics, they created and are now selling the first cure for sickle cell disease and beta thalassemia, or are they already big pharma?? 😀
it’s inevitable that the big companies with lots of capital buy out the small innovative companies or fund the trials as long as it helps the bottom line.
I have always seen competition in the field of medicine as a zero sum game: if one company has the tools to grab the whole market, it would grab the whole market. That's why I do not believe anyone is hiding a cure. Because ego means more than money (as most billionaires often demonstrate), but mainly because if my company would be able to cure even just one kind of cancer (especially if a common one) I would make sure everyone knows it, my stock shares would skyrocket and I would take 100% of the market for enough years to make it virtually mine forever. I could take a risk and delay the development or commercialization because I want to recover the money spent on a less powerful drug, but it would be a huge risk, someone else could come out with a different solution meanwhile 😀😀
Unmetabolized Estrogen (Depurinated Adducts) How I got PCa and how to prevent and detect it.
EMBARK Study: Enzalutamide +/- ADTPinostilbene inhibits the Enz-resistant CRPC cell line by inhibiting AR variant 7this is simply too cool: not directly related to PCa but worth a read
Fish consumption and PCa Mortality. A meta-analysis.
